NCT06931496 (PROSTIA- BP) is a NA clinical trial of PROSTia test in Prostate Cancer (Adenocarcinoma), sponsored by Central Hospital, Nancy, France.

Who is sponsoring NCT06931496?

NCT06931496 is sponsored by Central Hospital, Nancy, France.

What drugs are being tested in NCT06931496?

Interventions in NCT06931496: PROSTia test.

What condition does NCT06931496 study?

NCT06931496 studies Prostate Cancer (Adenocarcinoma).

Is NCT06931496 still recruiting?

NCT06931496 is currently not yet recruiting. Last updated 17 April 2025.

Last reviewed 2025-04-17 · How we verify

NCT06931496: PROSTIA- BP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of the PROSTia Test in Patients Undergoing Prostate Biopsy

Not yet recruiting NA Last updated 17 April 2025

What this trial tests

NA trial testing PROSTia test in Prostate Cancer (Adenocarcinoma) in 150 participants. Not yet recruiting.

Timeline

15 April 2025

Primary endpoint
1 September 2025

1 November 2025

Quick facts

Lead sponsor	Central Hospital, Nancy, France
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	150
Start date	15 April 2025
Primary completion	1 September 2025
Estimated completion	1 November 2025
Sites	1 location across France

Drugs / interventions tested

PROSTia test

Conditions studied

Prostate Cancer (Adenocarcinoma) — all drugs for Prostate Cancer (Adenocarcinoma) →

Sponsor

Central Hospital, Nancy, France

Who can join

18 and older, male only, with Prostate Cancer (Adenocarcinoma). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators are interested here in the contribution of a new prostate cancer screening method and, more specifically, in the new and somewhat futuristic approach of artificial intelligence in the development of new, more accurate algorithms that make it possible to rethink the benefits of mass generalisation of prostate biopsies. Main objective The main objective of this research is to use artificial intelligence and an associated algorithm to identify new indicators that would make it possible to avoid a prostate biopsy in patients with an initial suspicion of prostate cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Prostate Cancer (Adenocarcinoma)

Currently open trials in the same condition.

NCT07407608 — ABlative Radiotherapy (for) Unfavorable Prostate Tumors 2.0 · recruiting
NCT06957691 — Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Pro · Phase 2 · recruiting
NCT07363382 — The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer · Phase 1, PHASE2 · recruiting
NCT07302451 — REDI-CaP(Recovery of Erectile Dysfunction Induced in Prostate Cancer Patients) · Phase 2 · active not recruiting
NCT07115914 — PSMA PET for Surveillance After Focal Therapy · NA · recruiting

Other Central Hospital, Nancy, France trials

Trials by the same sponsor.

NCT06452290 — PET Biomarker Study for Antidepressant Response Prediction in Major Depressive Disorder · NA · not yet recruiting
NCT07518498 — Hypnosis During Mechanical Ventilation Weaning · NA · not yet recruiting
NCT07471334 — Prospective Study of Postictal Psychotic Symptoms Occuring After Video-EEG Monitoring in Focal Epilepsies · NA · not yet recruiting
NCT07414667 — Primary Sjögren's Syndrome: Impact of Quantitative Anti-Ro52 Antibody Analysis on Patient Prognosis and Stratification ( · not yet recruiting
NCT07415759 — Imaging of Electrical Properties by MRI: Investigation of Age-Related Changes · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06931496 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Central Hospital, Nancy, France
Last refreshed: 17 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06931496.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing